Based on the above observations, in this study, we hypothesised that despite important overlaps in their clinical presentation, sPD and LRRK2-PD might have a different molecular signature and therefore the molecular alterations contributing to disease onset and progression might be functionally different. Here, LRRK2 is linked to Parkinson disease.